![Michael McCullar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael McCullar
Chief Executive Officer at Regcell KK
Profile
Michael V.
McCullar currently works at Regcell KK, as President, CEO & Representative Director from 2023.
Dr. McCullar also formerly worked at SuperGen, Inc., as Vice President-Drug Discovery Operations, Titan Pharmaceuticals, Inc., as Principal, Astex Therapeutics Ltd., as Senior Vice President-Business Development, Leukemia & Lymphoma Society Greater San Francisco Bay Area, as Trustee, and Astex Pharmaceuticals, Inc., as Senior VP-Strategy & Discovery Operations from 2000 to 2012.
Dr. McCullar received his doctorate degree from the University of California and Masters Business Admin degree from W.P.
Carey School of Business.
Michael McCullar active positions
Companies | Position | Start |
---|---|---|
Regcell KK
![]() Regcell KK BiotechnologyHealth Technology Regcell KK develops immune system control technologies for the treatment of autoimmune diseases. The company is based in Kyoto, Japan. The Japanese company was founded in 2016 by Shimon Sakaguchi. | Chief Executive Officer | 19/10/2023 |
Former positions of Michael McCullar
Companies | Position | End |
---|---|---|
SuperGen, Inc.
![]() SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Corporate Officer/Principal | 13/09/2011 |
Leukemia & Lymphoma Society Greater San Francisco Bay Area | Director/Board Member | - |
TITAN PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Astex Therapeutics Ltd.
![]() Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
Astex Pharmaceuticals, Inc.
![]() Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded in March 1991 and is headquartered in Pleasanton, CA. | Corporate Officer/Principal | - |
Training of Michael McCullar
University of California | Doctorate Degree |
W.P. Carey School of Business | Masters Business Admin |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
TITAN PHARMACEUTICALS, INC. | Health Technology |
Private companies | 5 |
---|---|
SuperGen, Inc.
![]() SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Astex Therapeutics Ltd.
![]() Astex Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Leukemia & Lymphoma Society Greater San Francisco Bay Area | |
Astex Pharmaceuticals, Inc.
![]() Astex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Astex Pharmaceuticals, Inc. researches and develops oncology drugs. It is dedicated to the discovery, development, and commercialization of novel therapeutics with a focus on cancer. Its products include Guadecitabine, Onalespib, AT7519, AT13148, ASTX727, ASTX660. The company was founded in March 1991 and is headquartered in Pleasanton, CA. | Health Technology |
Regcell KK
![]() Regcell KK BiotechnologyHealth Technology Regcell KK develops immune system control technologies for the treatment of autoimmune diseases. The company is based in Kyoto, Japan. The Japanese company was founded in 2016 by Shimon Sakaguchi. | Health Technology |
- Stock Market
- Insiders
- Michael McCullar